Arovella Therapeutics

What Arovella Therapeutics does

Arovella Therapeutics (ASX: ALA) is a clinical-stage Australian biotechnology company developing allogeneic, off-the-shelf CAR-iNKT (invariant Natural Killer T) cell therapies for cancer. Its lead asset, ALA-101 (CAR19-iNKT), is an allogeneic CAR-iNKT product targeting CD19+ B cell lymphomas and leukemias for which the company submitted an Investigational New Drug application to the US FDA in December 2025 to initiate a first-in-human Phase 1 trial. Its second asset, ALA-105 (CLDN18.2-iNKT), targets Claudin 18.2-positive solid tumours — including gastric, gastroesophageal junction, pancreatic, and selected lung and ovarian cancers — under a global exclusive licence from Sparx Group for the SPX-101 monoclonal antibody sequence.

The core platform combines three killing mechanisms in a single engineered cell: CAR-mediated antigen recognition, natural CD1d targeting via the invariant T cell receptor, and the NKG2D pathway. Arovella layers a proprietary membrane-anchored interleukin-12 construct (IL-12-TM) onto its CAR-iNKT cells to enhance proliferation, persistence, and antitumour activity in solid tumour models while avoiding systemic cytokine exposure. The platform was invented at Imperial College London by Professor Anastasios Karadimitris and is supported by ongoing research collaborations with Imperial, the University of North Carolina (Professor Gianpietro Dotti), and King's College London (Dr John Maher and Dr Reuben Benjamin). Granted patents cover both the proprietary CAR-iNKT manufacturing process and the IL-12-TM technology.

Arovella is pre-revenue, with no commercial product sales. Its business model contemplates future revenue from licensing and royalty arrangements, including the Sparx Group collaboration, and ultimately from therapeutic product sales once ALA-101 or ALA-105 receive regulatory approval. The company operates with a small team of approximately 11–50 employees based in Australia, and is led by Acting CEO Dr Nicole van der Weerden under Chairman David Williams, with executive oversight across manufacturing, clinical development, and R&D.

Name

Arovella Therapeutics

Legal name

Arovella Therapeutics Limited

Website

https://arovella.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

Arovella Therapeutics is a clinical-stage Australian biotechnology company developing off-the-shelf CAR-iNKT cell therapies for hematological cancers (ALA-101) and solid tumours (ALA-105), leveraging proprietary IL-12-TM cytokine armouring and academic collaborations originating from Imperial College London.

Ownership category

akta.pro rank

Product category

Oncology Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Cell therapy platform
• CAR-iNKT therapy
• Oncology biopharmaceuticals
• Allogeneic cell therapy
• Cancer immunotherapy

Headquarters

HQ city

Perth

HQ country

Australia

HQ region

Oceania

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Therapeutic Product Sales: Pre-revenue biopharmaceutical company developing iNKT cell therapy products. Revenue will be generated from sales of approved cell therapy products (ALA-101 and ALA-105) upon successful clinical development and regulatory approval.
2. Licensing and Partnership Revenue: Potential licensing deals and strategic partnerships for its technology platform and therapeutic candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Arovella Therapeutics develops allogeneic CAR-iNKT (invariant Natural Killer T) cell therapies for cancer treatment. Its lead product, ALA-101, is an off-the-shelf CAR-iNKT cell therapy targeting CD19+ B cell lymphomas and leukemias, with an IND application submitted to the US FDA in December 2025 for a Phase 1 trial. Its second program, ALA-105, targets CLDN18.2 for solid tumours such as gastric, gastroesophageal junction, and pancreatic cancers, and uses proprietary IL-12-TM cytokine technology to armour the cells for enhanced anti-tumour activity.

Product overview

Arovella Therapeutics is a biotechnology company developing an iNKT cell therapy platform to treat cancer. The platform comprises two lead products: ALA-101 (CAR19-iNKT), an off-the-shelf allogeneic CAR-iNKT cell therapy targeting CD19+ blood cancers currently in Phase 1 clinical trials, and ALA-105 (CLDN18.2-iNKT), a solid tumor targeting therapy. The company also employs IL-12-TM cytokine technology to armor its CAR-iNKT cells for enhanced proliferation and antitumor activity. The iNKT cell platform enables multi-targeting cancer cell killing through CAR recognition, CD1d targeting, and NKG2D pathway activation.

Differentiator

Problem solved

Functional benefit

Brands

• ALA-101: CD19-targeting CAR-iNKT cell therapy for blood cancers
• ALA-105
• IL-12-TM

Quantifiable outcome

• CAR-iNKT cells demonstrate increased activity over conventional T cell therapies in preclinical studies due to multiple targeting and killing mechanisms
• +1 more outcomes

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Sparx GroupcoreTechnology or IntegrationArovella has entered into a global, exclusive license agreement with Sparx Group to develop CAR-iNKT cells targeting Claudin 18.2 (CLDN18.2) using Sparx's novel monoclonal antibody sequence SPX-101. This partnership enables development of world-first iNKT cell therapy for solid tumours including gastric cancer, gastroesophageal junction cancer, and pancreatic cancer.
• Imperial College LondoncoreStrategic or Co-development PartnerResearch collaboration with Imperial College London, where Professor Anastasios Karadimitris serves as inventor and investigator of the iNKT cell therapy platform. Research collaborators from Imperial presented data using Arovella's CAR-iNKT cell therapy platform at the 65th ASH Annual Meeting (December 2023). Professor Karadimitris is Chair and Director of the Hugh and Josseline Langmuir Centre for Myeloma Research and co-Director of the Centre for Haematology at Imperial College London.
• University of North CarolinacoreStrategic or Co-development PartnerCollaboration with Professor Gianpietro Dotti at UNC Lineberger Comprehensive Cancer Center, a leading researcher in engineered immune cells for cancer treatment with over 200 peer-reviewed publications and Highly Cited Researcher recognition (2020-2023).
• King's College LondoncoreStrategic or Co-development PartnerCollaboration with Dr John Maher (CAR Mechanics group) and Dr Reuben Benjamin (CALM Trial chief investigator) at King's College London. Dr Maher established CAR T cell research at King's in 2004; Dr Benjamin leads the plasma cell disorder service and CAR-T cell programme.
• Nature Publishing GroupminorOthersPublication of peer-reviewed research in Nature Communications (IL-12 reprogramming paper) and Nature Cancer journal, demonstrating scientific credibility and academic collaboration.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Adaptimmune Therapeutics: Engineered TCR-T cell therapy developer (Tecelra approved for synovial sarcoma). Comparable cellular immunotherapy modality with overlapping solid-tumour ambitions, though autologous.
• Atara Biotherapeutics: Allogeneic T-cell immunotherapy developer (EBV-specific and CAR-T programs including a licensed CD19 program). Adjacent allogeneic cell therapy competitor with established clinical-stage experience.
• Precision BioSciences: Allogeneic CAR-T programs using ARCUS gene editing, including CD19 candidates. Comparable allogeneic, off-the-shelf positioning to Arovella, though with different gene-editing platform.
• CRISPR Therapeutics: Gene-edited allogeneic CAR-T programs (e.g., CTX112 in CD19) plus partnerships with Vertex. Comparable allogeneic cell therapy modality with greater scale and approved-partner validation.

Direct peers

• Century Therapeutics: iPSC-derived allogeneic cell therapy developer for hematologic and solid tumours. Comparable platform-company structure with multi-target off-the-shelf cell therapy pipeline.
• Allogene Therapeutics: Clinical-stage allogeneic CAR-T developer with multiple CD19 and BCMA programs. Closest direct competitor to Arovella's off-the-shelf cell therapy thesis, with deeper clinical data and capital base but lacking iNKT biology.
• Fate Therapeutics: Develops off-the-shelf iPSC-derived NK and T-cell cancer immunotherapies. Highly comparable allogeneic, off-the-shelf cell therapy approach with similar CMC and scale-up dynamics to Arovella's CAR-iNKT platform.
• Caribou Biosciences: Allogeneic CAR-T developer using CRISPR-based gene editing. Direct peer in allogeneic CAR-T, targeting hematologic malignancies with off-the-shelf products.
• Nkarta Therapeutics: Allogeneic NK cell therapy developer with engineered CAR-NK programs for CD19 and other targets. Comparable allogeneic, off-the-shelf modality with similar target indications to ALA-101.

Broad incumbents

• Gilead (Kite Pharma): Owner of Yescarta and Tecartus (approved autologous CD19 CAR-Ts). Broad incumbent in CAR-T commercial market that Arovella's allogeneic platform aims to disrupt on cost and access.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/WeAreArovella
• Facebookfacebook.com/ArovellaTherapeutics
• LinkedInlinkedin.com/company/arovella-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arovella Therapeutics